Solid BiosciencesSLDB
About: Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Employees: 100
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
2,279% more call options, than puts
Call options by funds: $2.38M | Put options by funds: $100K
75% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 20
1.94% less ownership
Funds ownership: 92.86% [Q3] → 90.92% (-1.94%) [Q4]
2% less funds holding
Funds holding: 92 [Q3] → 90 (-2) [Q4]
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
42% less capital invested
Capital invested by funds: $250M [Q3] → $145M (-$105M) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Piper Sandler Biren Amin 17% 1-year accuracy 5 / 30 met price target | 514%upside $17 | Overweight Maintained | 16 May 2025 |
Wedbush Laura Chico 23% 1-year accuracy 10 / 44 met price target | 514%upside $17 | Outperform Maintained | 16 May 2025 |
Barclays Gena Wang 21% 1-year accuracy 7 / 33 met price target | 261%upside $10 | Overweight Maintained | 16 May 2025 |
JP Morgan Anupam Rama 21% 1-year accuracy 12 / 57 met price target | 297%upside $11 | Overweight Maintained | 13 Mar 2025 |
HC Wainwright & Co. Arthur He 9% 1-year accuracy 3 / 32 met price target | 622%upside $20 | Buy Maintained | 10 Mar 2025 |
Financial journalist opinion
Based on 4 articles about SLDB published over the past 30 days









